Clinical Trials

ARGX-113 in generalized myasthenia gravis

ARGX-113 is a novel FcRN antagonist shown to lower immunoglobulin levels in animals and man. This mechanism of action is now being studied in autoimmune diseases such as myasthenia gravis

To assess the safety and preliminary efficacy of ARGX-113 in generalized myasthenia gravis.


As above


Generalized myasthenia gravis, MGFA Class II to IVa, MG-ADL score at least 5, on stable immunosuppressive therapy or other agents for at least 3 months. Patients will receive the novel agent as an infusion of 10mg/kg versus placebo each week for 4 weeks, then are followed for an additional two months to assess persistence of response.




Gil I. Wolfe, Nicholas J. Silvestri

Contact Information

Name: Connie Brand
Phone: 716-859-7620